NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00009-0286-03 | 00009-0286 | Medroxyprogesterone Acetate | Provera | 5.0 mg/1 | Hormonal Therapy | Progestin | Oral | Jun 3, 1959 | Jun 30, 2019 | In Use | |
75840-0111-01 | 75840-0111 | Methotrexate sodium | Methotrexate Sodium | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct 1, 2012 | In Use | |
00591-4385-79 | 00591-4385 | fosaprepitant | Fosaprepitant | 150.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sep 19, 2019 | In Use | |
70710-1022-08 | 70710-1022 | Isotretinoin | Isotretinoin | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 12, 2023 | In Use | |
49884-0290-05 | 49884-0290 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug 8, 1988 | Dec 31, 2024 | In Use | |
50881-0005-60 | 50881-0005 | Ruxolitinib | Jakafi | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Nov 16, 2011 | In Use | |
50881-0010-01 | 50881-0010 | Ruxolitinib | Jakafi | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1 and JAK 2 (Janus Kinase Inhibitor) | Oral | Nov 16, 2011 | In Use | |
50881-0010-60 | 50881-0010 | Ruxolitinib | Jakafi | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1 and JAK 2 (Janus Kinase Inhibitor) | Oral | Nov 16, 2011 | In Use | |
50881-0015-60 | 50881-0015 | Ruxolitinib | Jakafi | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Nov 16, 2011 | In Use | |
54868-3310-00 | 54868-3310 | Leucovorin Calcium | Leucovorin Calcium | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Apr 15, 2002 | In Use | |
50881-0020-60 | 50881-0020 | Ruxolitinib | Jakafi | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Nov 16, 2011 | In Use | |
52549-4118-05 | 52549-4118 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Mar 5, 2010 | In Use | |
49884-0290-04 | 49884-0290 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug 8, 1988 | Sep 30, 2024 | In Use | |
49884-0289-01 | 49884-0289 | Megestrol Acetate | Megestrol Acetate | 20.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug 8, 1988 | Aug 31, 2024 | In Use | |
50881-0025-60 | 50881-0025 | Ruxolitinib | Jakafi | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Nov 16, 2011 | In Use | |
50881-0026-01 | 50881-0026 | Pemigatinib | PEMAZYRE | 4.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3 | Oral | Apr 17, 2020 | In Use | |
50881-0027-01 | 50881-0027 | Pemigatinib | PEMAZYRE | 9.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3 | Oral | Apr 17, 2020 | In Use | |
70860-0228-61 | 70860-0228 | Melphalan hydrochloride | Melphalan Hydrochloride | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Sep 1, 2023 | In Use | |
76282-0412-90 | 76282-0412 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 22, 2015 | In Use | |
50881-0028-01 | 50881-0028 | Pemigatinib | PEMAZYRE | 13.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3 | Oral | Apr 17, 2020 | In Use | |
00078-0640-70 | 00078-0640 | Ceritinib | Zykadia | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | Apr 29, 2014 | Feb 29, 2020 | In Use |
31722-0525-01 | 31722-0525 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug 1, 2010 | In Use | |
54868-3004-04 | 54868-3004 | Tamoxifen Citrate | Tamoxifen Citrate | 10.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Apr 26, 1994 | In Use | ||
54868-3004-03 | 54868-3004 | Tamoxifen Citrate | Tamoxifen Citrate | 10.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Apr 26, 1994 | In Use | ||
68118-0100-01 | 68118-0100 | Streptozocin | Zanosar | 1.0 g/10mL | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Feb 1, 2023 | In Use |
Found 11120 results — Export these results